Using information mining of the medical literature to improve drug safety

Journal of the American Medical Informatics Association

Volumn 18, Issue 5, 2011, Pages 668-674

  Shetty, Kanaka D ^a   Dalal, Siddhartha R ^a  

^a RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMLODIPINE BESYLATE; AMOXICILLIN; ATENOLOL; AZITHROMYCIN; CARVEDILOL; CELECOXIB; CETIRIZINE; ESOMEPRAZOLE; FEXOFENADINE; FUROSEMIDE; GABAPENTIN; GLIBENCLAMIDE; GLIPIZIDE; IBUPROFEN; LANSOPRAZOLE; LISINOPRIL; METFORMIN; METOPROLOL TARTRATE; NAPROXEN; PANTOPRAZOLE; PIOGLITAZONE; PRESCRIPTION DRUG; RAMIPRIL; ROFECOXIB; ROSIGLITAZONE; SPIRONOLACTONE; UNINDEXED DRUG; VALSARTAN; ZOLPIDEM;

ADVERSE OUTCOME; ARTICLE; DATA MINING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; MACHINE LEARNING; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDLINE; MESH HEADING; SENSITIVITY ANALYSIS;

DATA MINING; HUMANS; MEDICAL SUBJECT HEADINGS; NATURAL LANGUAGE PROCESSING; PRODUCT SURVEILLANCE, POSTMARKETING; PUBMED; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 80053254385     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1136/amiajnl-2011-000096     Document Type: Article

References (41)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
2. Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007;82:157-66.
3. Hochberg AM, Hauben M. Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria. Clin Pharmacol Ther 2009;85:600-6.
4. Hauben M, Noren GN. A decade of data mining and still counting. Drug Saf 2010;33:527-34.
5. Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf 2005;28:981-1007.
6. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142:481-9.
7. Edwards IR. What are the real lessons from Vioxx? Drug Saf 2005;28:651-8.
8. Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009;151:394-403.
9. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
10. Aubry M, Monnier A, Chicault C, et al. Combining evidence, biomedical literature and statistical dependence: new insights for functional annotation of gene sets. BMC Bioinformatics 2006;7:241.
11. Yetisgen-Yildiz M, Pratt W. Using statistical and knowledge-based approaches for literature-based discovery. J Biomed Inform 2006;39:600-11.
12. Tanaka LY, Herskovic JR, Iyengar MS, et al. Sequential result refinement for searching the biomedical literature. J Biomed Inform 2009;42:678-84.
13. Cohen AM, Hersh WR, Peterson K, et al. Reducing workload in systematic review preparation using automated citation classification. J Am Med Inform Assoc 2006;13:206-19.
14. Dalal S, Mallows C. Buying with exact confidence. Ann Appl Probab 1992;2:752-65.
15. Dalal S, Mallows C. Optimal stopping with exact confidence on remaining defects. Technometrics 2008;50:397-406.
16. Efron B. Large-scale simultaneous hypothesis testing: the choice of a null hypothesis. J Am Stat Assoc 2004;99:96-104.
17. Finner H, Roters M. Asymptotic comparison of step-down and step-up multiple test procedures based on exchangeable test statistics. Ann Stat 1998;26:505-24.
18. Lehmann E, Romano J. Generalizations of the familywise error rate. Ann Stat 2005;33:1138-54.
19. National Library of Medicine. Introduction to MeSHd2011, 2009. http://www.nlm.nih.gov/mesh/introduction.html (accessed 12 Nov 2009).
20. Pearson RK, Hauben M, Goldsmith DI, et al. Influence of the MedDRA((R)) hierarchy on pharmacovigilance data mining results. Int J Med Inform 2009;78:e97-e103.
21. NLM. DailyMed, 2009. http://dailymed.nlm.nih.gov/dailymed/about.cfm (accessed 25 Sep 2009).
22. Golder S, Loke YK. Search strategies to identify information on adverse effects: a systematic review. J Med Libr Asssoc 2009;97:84-92.
23. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
24. Shetty KD, Vogt WB, Bhattacharya J. Hormone replacement therapy and cardiovascular health in the United States. Med Care 2009;47:600-6.
25. Malik R, Franke L, Siebes A. Combination of text-mining algorithms increases the performance. Bioinformatics 2006;22:2151-7.
26. Chen ES, Hripcsak G, Xu H, et al. Automated acquisition of disease drug knowledge from biomedical and clinical documents: an initial study. J Am Med Inform Assoc 2008;15:87-98.
27. Tibshirani R. Regression shrinkage and selection by lasso. J Roy Stat Soc B 1994;58:267-88.
28. Genkin A, Lewis D, Madigan D. Large-scale bayesian logistic regression for text categorization. Technometrics 2007;49:291-304.
29. Friedman JH. Greedy function approximation: a gradient boosting machine. Ann Stat 2001;29:1189-232.
30. Efron B, Tibshirani R. Empirical bayes methods and false discovery rates for microarrays. Genet Epidemiol 2002;23:70-86.
31. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genomewide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
32. Payne PR, Starren JB. Quantifying visual similarity in clinical iconic graphics. J Am Med Inform Assoc 2005;12:338-45.
33. FDA. USFood and drug administration enforcement reports. 2009. http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm (accessed 5 Sep 2009).
34. Christopher-Stine L. Statin myopathy: an update. Curr Opin Rheumatol 2006;18:647-53.
35. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002;128:159-68.
36. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18(Suppl 2):S23-9.
37. van Rijsbergen CJ. Information Retrieval. London: Butterworths, 1979.
38. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95.
39. Hauben M. A brief primer on automated signal detection. Ann Pharmacother 2003;37:1117-23.
40. Avorn J. Drug warnings that can cause fitsecommunicating risks in a data-poor environment. N Engl J Med 2008;359:991-4.
41. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.